{"id":106142,"date":"2026-05-09T00:21:38","date_gmt":"2026-05-08T22:21:38","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=106142"},"modified":"2026-05-08T11:19:19","modified_gmt":"2026-05-08T09:19:19","slug":"spolecnost-biontech-zastavuje-vyrobu-sve-vakciny-proti-covid-19-a-propousti-1-860-pracovniku-po-ctvrtletni-ztrate-605-milionu-dolaru","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2026\/05\/09\/spolecnost-biontech-zastavuje-vyrobu-sve-vakciny-proti-covid-19-a-propousti-1-860-pracovniku-po-ctvrtletni-ztrate-605-milionu-dolaru\/","title":{"rendered":"Spole\u010dnost BioNTech zastavuje v\u00fdrobu sv\u00e9 vakc\u00edny proti COVID-19 a propou\u0161t\u00ed 1 860 pracovn\u00edk\u016f \u2013 po \u010dtvrtletn\u00ed ztr\u00e1t\u011b 605 milion\u016f dolar\u016f"},"content":{"rendered":"
<\/div>\n
\n
\n

N\u00e1sleduj\u00ed d\u016fle\u017eit\u00e1 rozhodnut\u00ed n\u011bmeck\u00fdch soud\u016f, kter\u00e1 na\u0159izuj\u00ed zve\u0159ejn\u011bn\u00ed intern\u00edch dokument\u016f o bezpe\u010dnosti a v\u00fdrob\u011b vakc\u00edn proti COVID-19.<\/span><\/strong><\/p>\n

Spole\u010dnost BioNTech ozn\u00e1mila, \u017ee pl\u00e1nuje uzav\u0159\u00edt v\u00fdznamn\u00e9 \u010d\u00e1sti sv\u00e9 v\u00fdrobn\u00ed s\u00edt\u011b vakc\u00edn proti COVID-19, uzav\u0159\u00edt n\u011bkolik z\u00e1vod\u016f, propustit p\u0159ibli\u017en\u011b 1 860 pracovn\u00edch m\u00edst a konsolidovat provoz, jeliko\u017e tr\u017eby z jej\u00edho podnik\u00e1n\u00ed s vakc\u00ednami proti COVID-19 nad\u00e1le klesaj\u00ed.<\/span><\/p>\n

Tento krok p\u0159ich\u00e1z\u00ed pot\u00e9, co kl\u00ed\u010dov\u00e1 rozhodnut\u00ed n\u011bmeck\u00e9ho soudu donutila spole\u010dnost BioNTech zve\u0159ejnit intern\u00ed \u00fadaje o bezpe\u010dnosti, toxicit\u011b, v\u00fdrob\u011b, biodistribuci, zbytc\u00edch DNA a spike proteinech jej\u00ed vakc\u00edny proti COVID-19 v r\u00e1mci soudn\u00edho sporu o po\u0161kozen\u00ed zdrav\u00ed zp\u016fsoben\u00e9 vakc\u00ednou, zat\u00edmco vy\u0161\u0161\u00ed odvolac\u00ed soud zru\u0161il rozhodnut\u00ed ni\u017e\u0161\u00edho soudu ve prosp\u011bch spole\u010dnosti a na\u0159\u00eddil \u00fapln\u00e9 p\u0159ezkoum\u00e1n\u00ed d\u016fkaz\u016f t\u00fdkaj\u00edc\u00edch se \u00fadajn\u00fdch po\u0161kozen\u00ed zdrav\u00ed zp\u016fsoben\u00fdch vakc\u00ednou, kter\u00e9 m\u011bn\u00ed \u017eivot.<\/span><\/p>\n

Podle ofici\u00e1ln\u00ed tiskov\u00e9 zpr\u00e1vy zve\u0159ejn\u011bn\u00e9 spole\u010dnost\u00ed BioNTech v \u00fater\u00fd ohledn\u011b finan\u010dn\u00edch v\u00fdsledk\u016f za prvn\u00ed \u010dtvrtlet\u00ed roku 2026:<\/span><\/p>\n

\u201eSpole\u010dnost BioNTech pl\u00e1nuje d\u00e1le zefektivnit a konsolidovat svou v\u00fdrobn\u00ed s\u00ed\u0165 v oblastech, kde se o\u010dek\u00e1v\u00e1 nadm\u011brn\u00e1 kapacita v d\u016fsledku m\u011bn\u00edc\u00edch se po\u017eadavk\u016f na dod\u00e1vky, f\u00faz\u00ed a akvizic, v\u00fdrobn\u00edch kapacit partner\u016f spole\u010dnosti BioNTech a vypr\u0161en\u00ed platnosti smluv.\u201c<\/span><\/em><\/p>\n

\u201eSpole\u010dnost BioNTech pl\u00e1nuje ukon\u010dit provoz ve sv\u00fdch v\u00fdrobn\u00edch z\u00e1vodech v Idar-Obersteinu, Marburgu a Singapuru, stejn\u011b jako v z\u00e1vodech spole\u010dnosti CureVac, co\u017e ovlivn\u00ed celkem p\u0159ibli\u017en\u011b 1 860 pracovn\u00edch m\u00edst. Ukon\u010den\u00ed provozu v z\u00e1vodech v Idar-Obersteinu, Marburgu a T\u00fcbingenu je pl\u00e1nov\u00e1no do konce roku 2027, zat\u00edmco provoz v Singapuru by m\u011bl b\u00fdt ukon\u010den v prvn\u00edm \u010dtvrtlet\u00ed roku 2027.\u201c<\/span><\/em><\/p>\n

\"\"<\/figure>\n

Spole\u010dnost BioNTech tak\u00e9 ozn\u00e1mila, \u017ee zva\u017euje prodej dot\u010den\u00fdch web\u016f:<\/span><\/p>\n

\u201eSpole\u010dnost BioNTech zkoum\u00e1 mo\u017enosti odprodeje pro ka\u017ed\u00fd z t\u011bchto v\u00fdrobn\u00edch z\u00e1vod\u016f, v\u010detn\u011b \u010d\u00e1ste\u010dn\u00e9ho nebo \u00fapln\u00e9ho prodeje.\u201c<\/span><\/em><\/p>\n

Spole\u010dnost uvedla, \u017ee se o\u010dek\u00e1v\u00e1, \u017ee restrukturalizace povede k masivn\u00edmu dlouhodob\u00e9mu sn\u00ed\u017een\u00ed n\u00e1klad\u016f:<\/span><\/p>\n

\u201eSpole\u010dnost BioNTech o\u010dek\u00e1v\u00e1, \u017ee \u00faspory n\u00e1klad\u016f se budou v pr\u016fb\u011bhu \u010dasu zvy\u0161ovat a po \u00fapln\u00e9m zaveden\u00ed opat\u0159en\u00ed v roce 2029 by mohly dos\u00e1hnout opakovan\u00fdch ro\u010dn\u00edch \u00faspor ve v\u00fd\u0161i p\u0159ibli\u017en\u011b 500 milion\u016f eur.\u201c<\/span><\/em><\/p>\n

Toto ozn\u00e1men\u00ed p\u0159ich\u00e1z\u00ed na pozad\u00ed zpr\u00e1v spole\u010dnosti BioNTech o poklesu prodeje vakc\u00edn proti COVID-19 a zhor\u0161uj\u00edc\u00edch se finan\u010dn\u00edch ztr\u00e1t\u00e1ch.<\/span><\/p>\n

Podle spole\u010dnosti:<\/span><\/p>\n

\u201eTr\u017eby v prvn\u00edm \u010dtvrtlet\u00ed roku 2026 dos\u00e1hly 118,1 milionu eur, oproti 182,8 milionu eur ve stejn\u00e9m obdob\u00ed p\u0159edchoz\u00edho roku. Pokles byl zp\u016fsoben p\u0159edev\u0161\u00edm ni\u017e\u0161\u00edmi prodeji vakc\u00edn proti COVID-19 spole\u010dnosti BioNTech.\u201c<\/span><\/em><\/p>\n

BioNTech tak\u00e9 informoval:<\/span><\/p>\n

\u201e\u010cist\u00e1 ztr\u00e1ta v prvn\u00edm \u010dtvrtlet\u00ed roku 2026 dos\u00e1hla 531,9 milionu eur (cca 605 milion\u016f americk\u00fdch dolar\u016f), oproti \u010dist\u00e9 ztr\u00e1t\u011b 415,8 milionu eur ve stejn\u00e9m obdob\u00ed p\u0159edchoz\u00edho roku.\u201c<\/span><\/em><\/p>\n

Spole\u010dnost uznala, \u017ee v budoucnu lze o\u010dek\u00e1vat dal\u0161\u00ed pokles prodeje vakc\u00edn proti COVID-19.<\/span><\/p>\n

\u201eSpole\u010dnost BioNTech o\u010dek\u00e1v\u00e1 v roce 2026 ni\u017e\u0161\u00ed prodej vakc\u00edn proti COVID-19 ve srovn\u00e1n\u00ed s rokem 2025, a to v d\u016fsledku poklesu na evropsk\u00e9m i americk\u00e9m trhu.\u201c<\/span><\/em><\/p>\n

BioNTech d\u00e1le vysv\u011btlil:<\/span><\/p>\n

\u201eV Evrop\u011b spole\u010dnost o\u010dek\u00e1v\u00e1 ni\u017e\u0161\u00ed tr\u017eby, proto\u017ee si br\u00e1n\u00ed sv\u016fj pod\u00edl na trhu a za\u010d\u00edn\u00e1 zvl\u00e1dat p\u0159echod od v\u00edcelet\u00fdch smluv.\u201c<\/span><\/em><\/p>\n

Samostatn\u00e1 zpr\u00e1va Pharmaphorum, zve\u0159ejn\u011bn\u00e1 ve st\u0159edu, uv\u00e1d\u00ed, \u017ee BioNTech fakticky zastavuje v\u00fdrobu vakc\u00edn proti COVID-19 a p\u0159ev\u00e1d\u00ed odpov\u011bdnost za v\u00fdrobu na spole\u010dnost Pfizer.<\/span><\/p>\n

\u201eSpole\u010dnost BioNTech ozn\u00e1mila, \u017ee ukon\u010d\u00ed v\u00fdrobu vakc\u00edn proti COVID-19, aby dos\u00e1hla ro\u010dn\u00edch \u00faspor ve v\u00fd\u0161i p\u0159ibli\u017en\u011b 500 milion\u016f eur, a p\u0159evede odpov\u011bdnost za v\u00fdrobu d\u00e1vek vakc\u00edny na sv\u00e9ho partnera Pfizer.\u201c<\/span><\/em><\/p>\n

\u201eOzn\u00e1men\u00ed p\u0159i\u0161lo jako sou\u010d\u00e1st zpr\u00e1vy n\u011bmeck\u00e9 biotechnologick\u00e9 spole\u010dnosti za prvn\u00ed \u010dtvrtlet\u00ed, v n\u00ed\u017e odhalila pl\u00e1ny na uzav\u0159en\u00ed v\u00fdrobn\u00edch z\u00e1vod\u016f v N\u011bmecku a Singapuru, co\u017e povede ke ztr\u00e1t\u011b p\u0159ibli\u017en\u011b 1 860 pracovn\u00edch m\u00edst \u2013 zhruba 22 % celkov\u00e9ho po\u010dtu 8 400 zam\u011bstnanc\u016f.\u201c<\/span><\/em><\/p>\n

\"\"<\/figure>\n

Zat\u00edmco BioNTech uzav\u00edr\u00e1 velk\u00e9 \u010d\u00e1sti sv\u00e9 v\u00fdrobn\u00ed infrastruktury pro COVID-19, spole\u010dnost st\u00e1le v\u00edce p\u0159esm\u011brov\u00e1v\u00e1 sv\u00e9 zdroje do onkologie a mRNA terapi\u00ed rakoviny.<\/span><\/p>\n

Tiskov\u00e1 zpr\u00e1va spole\u010dnosti BioNTech uv\u00e1d\u00ed:<\/span><\/p>\n

\u201eProvozn\u00ed efektivita se zv\u00fd\u0161\u00ed konsolidac\u00ed v\u00fdrobn\u00edch z\u00e1vod\u016f, co\u017e podpo\u0159\u00ed strategickou alokaci kapit\u00e1lu pro dal\u0161\u00ed rozvoj rostouc\u00edho onkologick\u00e9ho portfolia sm\u011brem k uveden\u00ed na trh.\u201c<\/span><\/em><\/p>\n

\u2026<\/span><\/h2>\n

\u201eSpole\u010dnost BioNTech bude i nad\u00e1le zam\u011b\u0159ovat sv\u00e9 investice na v\u00fdzkum a v\u00fdvoj a tak\u00e9 na roz\u0161i\u0159ov\u00e1n\u00ed sv\u00e9ho podnik\u00e1n\u00ed v oblasti onkologie v pokro\u010dil\u00fdch f\u00e1z\u00edch v\u00fdvoje a p\u0159ipravenosti na trh.\u201c<\/span><\/em><\/p>\n

A gener\u00e1ln\u00ed \u0159editel Ugur Sahin \u0159ekl:<\/span><\/p>\n

\u201eBudeme se i nad\u00e1le zam\u011b\u0159ovat na rozvoj na\u0161ich kl\u00ed\u010dov\u00fdch strategick\u00fdch program\u016f a z\u00e1rove\u0148 neochv\u011bjn\u011b dr\u017eet se na\u0161\u00ed vize p\u0159ev\u00e9st na\u0161i v\u011bdu do opat\u0159en\u00ed prodlu\u017euj\u00edc\u00edch \u017eivot pacient\u016f s rakovinou.\u201c<\/span><\/em><\/p>\n

Navzdory uzav\u0159en\u00ed v\u00fdroby spole\u010dnost BioNTech potvrdila, \u017ee i nad\u00e1le p\u0159ipravuje aktualizovan\u00e9 vakc\u00edny proti COVID-19 pro nadch\u00e1zej\u00edc\u00ed o\u010dkovac\u00ed cyklus.<\/span><\/p>\n

\u201eBioNTech se nyn\u00ed zam\u011b\u0159uje na p\u0159\u00edpravu adaptace vakc\u00edny na varianty viru, aby byla p\u0159ipravena k uveden\u00ed na trh p\u0159ed nadch\u00e1zej\u00edc\u00ed o\u010dkovac\u00ed sez\u00f3nou 2026\/2027, v z\u00e1vislosti na schv\u00e1len\u00ed.\u201c<\/span><\/em><\/p>\n

Od Jona Fleetwooda<\/span><\/em><\/strong><\/p>\n<\/div>\n<\/div>\n

\n
\n

Zdroj<\/span><\/a><\/span><\/h3>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

N\u00e1sleduj\u00ed d\u016fle\u017eit\u00e1 rozhodnut\u00ed n\u011bmeck\u00fdch soud\u016f, kter\u00e1 na\u0159izuj\u00ed zve\u0159ejn\u011bn\u00ed intern\u00edch dokument\u016f o bezpe\u010dnosti a v\u00fdrob\u011b vakc\u00edn…<\/p>\n","protected":false},"author":2,"featured_media":106143,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[4274,1503,371,651],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/106142"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=106142"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/106142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/106143"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=106142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=106142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=106142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}